Amarin Corp Plc (AMRN)

[HDGabor]

My understanding of the studies / BD:

1.) Equal or less than 2g is not efficient (as V 2g) - agree, but it is 4g. (statins are also optimized)
2.) If TG is below 200/150 no cardiovascular treatment benefit - agree, but it is TG above 200. (with optimal parameters nobody needs statin.)
3.) Subgroup analyses from JELIS, ACCORD-Lipid, and AIM-HIGH suggested that patients with elevated TG and low HDL-C might experience a greater potential treatment benefit with additional lipid modifiers to a statin regimen; however, the available HPS2-THRIVE subgroup analyses do not seem to support this hypothesis. Unfortunately, none of these trials were specifically designed to recruit and investigate patients with moderate hypertriglyceridemia with or without low HDL-C; therefore, these results are hypothesis-generating and require validation. - agree, BUT this is the CURRENT assumption / sciense.

So I do not see it as substantial scientific issue essential to determining the safety or efficacy. It just say these results are hypothesis and require validation.